RVMD
Revolution Medicines, Inc.
Stock
$205.26+0.78 (+0.38%)Close Sep 30, 2026
Cash flow statement
| Line | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | −$1.2B | −$898M | −$557M | −$351M | −$224M | −$147M | −$100M | −$50M | $1.2M |
| Capital expenditures | $9.1M | $16M | $10M | $7.7M | $11M | $6.5M | $2.9M | $2.6M | $1.5M |
| Free cash flow | −$1.2B | −$914M | −$568M | −$358M | −$235M | −$154M | −$103M | −$52M | −$286K |
| Stock-based compensation | $219M | $118M | $79M | $62M | $31M | $21M | $8.9M | $3.2M | $855K |
| Dividends paid | — | — | — | — | — | — | $0 | — | — |
| Free cash flow margin | — | — | — | −3,094.1% | −664.8% | −523.0% | −239.6% | −104.3% | −1.4% |